Home Tags Claudin 18.2
Tag: Claudin 18.2
ATG-022, a Claudin 18.2 ADC, Receives Orphan Drug Designations for the...
Shanghai-based biopharmaceutical company Antengene, confirmed that ATG-022, a Claudin 18.2 (CLDN18.2) antibody drug conjugate (ADC) being developed by the company, has been granted two Orphan Drug Designations (ODD) consecutively by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer.
LaNova Signs Exclusive License Agreement with AstraZeneca for Novel GPRC5D-Targeting ADC
LaNova Medicines and AstraZeneca have entered into an exclusive license agreement with for LM-305, a pre-clinical stage antibody-drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).
AstraZeneca Enters License Agreement with KYM Biosciences for CMG901
AstraZeneca has signed an exclusive global license agreement with KYM Biosciences, a joint venture of Keymed Biosciences and Lepu Biopharma, for CMG901.
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021
Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, said it will prioritize key research and development efforts to advance EO-3021 (SYSA1801), its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin 18.2, and other pipeline programs including those through its existing partnership with Caris Life Sciences.
RC118 Targeting Claudin 18.2 ADC Receives Two Orphan Drug Designations
RC118, an antibody-drug conjugates or ADC being developed by RemeGen, a commercial-stage biotechnology company based in Yantai, China, has been granted two orphan drug...
WuXi XDC and AbTis to Collaborate in the Development and Manufacturing...
Chinese WuXi XDC, a joint venture between WuXi Biologics and WuXi STA, a Contract Research, Development and Manufacturing Organization focusing on end-to-end bioconjugates services, and...